---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000023"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T11:39:26.374338+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neurocrine settles INGREZZA patent litigation with Teva; generic entry allowed Feb 2040

## Summary
- Settlement grants Teva right to sell generic INGREZZA in the U.S. starting February 1, 2040, or earlier under certain conditions.
- Agreement resolves ANDA patent litigation filed in District of Delaware; terms to be submitted to FTC and DOJ.
- Patent litigation against three other ANDA filers for generic INGREZZA remains pending, trial scheduled for January 2, 2024.

## SEC filing metadata
- accession: 0000914475-23-000023
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000023/0000914475-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000023/nbix-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000023
- JSON: https://secwatch.observer/filing/0000914475-23-000023.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.